Oral Roxadustat in Anemia Secondary to Lower-Risk MDS: 1-Yr Analysis

December 5-8, 2020; Online at https://www.hematology.org/meetings/annual-meeting
Updated data on roxadustat in patients with lower-risk MDS from the open-label portion of an ongoing randomized, double-blind phase III study suggest that roxadustat reduces transfusion burden and enables transfusion independence.
Format: Microsoft PowerPoint (.ppt)
File Size: 414 KB
Released: December 14, 2020


Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
Bristol-Myers Squibb
Epizyme Inc.
Incyte Corporation
Janssen Biotech, Inc.
Karyopharm Therapeutics Inc.
PharmaEssentia Corp.
Takeda Oncology

Related Content

Experts highlight key studies being presented at the 2022 ASH Annual Meeting in this commentary from Clinical Care Options (CCO)

Catherine M. Broome, MD John M. Burke, MD Corey Cutler, MD, MPH, FRCPC person default David Dingli, MD, PhD Amir T. Fathi, MD Shaji K. Kumar, MD Sagar Lonial, MD Peter Martin, MD Marshall Mazepa, MD Srdan Verstovsek, MD, PhD Eunice S. Wang, MD Allison Wheeler, MD, MSCI Amer Zeidan, MBBS, MPH Released: December 7, 2022

Case-based downloadable slideset on diagnosis of MDS focusing on ring sideroblasts and SF3B1 mutations, from Clinical Care Options (CCO)

Tal Oren, MD, PhD Released: October 7, 2022

Downloadable slideset from Alexa Siddon, MD, on identifying ring sideroblasts and SF3B1 mutations in MDS, from Clinical Care Options (CCO)

Alexa J. Siddon, MD Released: October 7, 2022

Downloadable slideset from Cecilia Yeung, MD, on the newest MDS classification guidelines, provided by Clinical Care Options (CCO)

Cecilia Yeung, MD Released: October 7, 2022

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.


Cookie Settings